Insulin Aspart (Niacinamide)
Brand name: Fiasp Flextouch
Rank #364 of 500 drugs by total cost
$27.0M
Total Cost
24,598
Total Claims
$27.0M
Total Cost
1,185
Prescribers
$1,096
Cost per Claim
2,931
Beneficiaries
42,511
30-Day Fills
$23K
Avg Cost/Provider
21
Avg Claims/Provider
About Insulin Aspart (Niacinamide)
Insulin Aspart (Niacinamide) (sold as Fiasp Flextouch) was prescribed 24,598 times by 1,185 Medicare Part D providers in 2023, costing the program $27.0M. At $1,096 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 361 | Trifluridine/Tipiracil Hcl (Lonsurf) | $27.3M | 2,430 |
| 362 | Memantine Hcl/Donepezil Hcl (Namzaric) | $27.2M | 46,134 |
| 363 | Solifenacin Succinate (Solifenacin Succinate) | $27.1M | 343,174 |
| 364 | Insulin Aspart (Niacinamide) (Fiasp Flextouch) | $27.0M | 24,598 |
| 365 | Lisinopril/Hydrochlorothiazide (Lisinopril-Hydrochlorothiazide) | $26.8M | 2,304,445 |
| 366 | Dofetilide (Dofetilide) | $26.7M | 98,814 |
| 367 | Plecanatide (Trulance) | $26.6M | 36,026 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology